3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Conditions
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Head and Neck Neoplasms
1
Interventions
pembrolizumab
166
Cisplatin
112
Cetuximab
76
Nivolumab
52
Carboplatin
51
Fluorouracil
48
Paclitaxel
42
Docetaxel
37
Gemcitabine
30
Radiotherapy
28
Capecitabine
19
Cyclophosphamide
18
durvalumab
17
Injections
17
lenvatinib
16
atezolizumab
16
cemiplimab
15
spartalizumab
13
fludarabine
13
avelumab
12
Ipilimumab
12
Pemetrexed
11
130-nm albumin-bound paclitaxel
11
Oxaliplatin
10
Gefitinib
10
tremelimumab
9
Drug Therapy
9
tislelizumab
8
epacadostat
8
budigalimab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
combretastatin
×
Head & Neck
×
Clear all
NCT00507429
2014-06-09
FACT
Mateon Therapeutics
Phase 2/3
Terminated
80 enrolled
10 charts
NCT01701349
2014-05-01
FACT2
Mateon Therapeutics
Phase 3
Withdrawn